Lessons from the Helsinki Heart Study. Fibric acid therapy for dyslipidemia

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


The detection and treatment of high blood cholesterol as a means of improving cardiovascular health is receiving major attention in medical practice. Results of the Helsinki Heart Study, which examined the effects of treatment with the fibric acid gemfibrozil (Lopid) in hypercholesterolemic men, showed a reduction in coronary heart disease apparently attributable to decreased low-density lipoprotein cholesterol and plasma triglyceride levels and/or increased high-density lipoprotein cholesterol levels. No increase in mortality or in the incidence of serious side effects occurred with treatment. Although fibric acid therapy remains controversial, its use in selected patients appears to be justified.

Original languageEnglish (US)
Pages (from-to)217-231
Number of pages15
JournalPostgraduate medicine
Issue number1
StatePublished - Jan 1 1988

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Lessons from the Helsinki Heart Study. Fibric acid therapy for dyslipidemia'. Together they form a unique fingerprint.

Cite this